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Background: Recruiting participants to multicentre, community-based trials is a challenge. This case study describes
how this challenge was met for the BeWEL trial, which evaluated the impact of a diet and physical activity
intervention on body weight in people who had had pre-cancerous bowel polyps.
Methods: The BeWEL trial was a community-based trial, involving centres linked to the Scottish National Health
Service (NHS) colorectal cancer screening programme. BeWEL had a recruitment target of 316 and its primary
recruitment route was the colonoscopy clinics of the Scottish Bowel Screening Programme.
Results: BeWEL exceeded its recruitment target but needed a 6-month no-cost extension from the funder to
achieve this. The major causes of delay were lower consent rates (49% as opposed to 70% estimated from earlier
work), the time taken for NHS research and development department approvals and the inclusion of two additional
sites to increase recruitment, for which there were substantial bureaucratic delays. A range of specific interventions
to increase recruitment, for example, telephone reminders and a shorter participant information leaflet, helped to
increase the proportion of eligible individuals consenting and being randomized.
Conclusions: Recruitment to multicentre trials is a challenge but can be successfully achieved with a committed
team. In a UK context, NHS research and development approval can be a substantial source of delay. Investigators
should be cautious when estimating consent rates. If consent rates are less than expected, qualitative analysis
might be beneficial, to try and identify the reason. Finally, investigators should select trial sites on the basis of a
formal assessment of a site’s past performance and the likelihood of success in the trial being planned.
Trial registration: Current Controlled Trials ISRCTN53033856
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Randomized controlled trials (RCTs) are the gold standard
for the evaluation of the effectiveness and safety of health-
care interventions, particularly because they protect against
selection bias [1]. However, recruiting health professionals
and patients to RCTs can be extremely difficult: studies of
recruitment suggest that at least 45% of studies fail to
achieve their recruitment targets, although those involving
a clinical trials unit do somewhat better, with 65% (20/31)* Correspondence: streweek@mac.com
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reproduction in any medium, provided the orof trials recruiting to target [2,3]. This may result in an
underpowered trial, which, in turn, may lead to non-
significant results that nevertheless do not rule out the pos-
sibility of important benefits. Recruitment failings increase
the risk that an effective intervention will be abandoned
before its true value is appreciated, or can lead to delays in
demonstrating the benefits of an intervention while further
trials are conducted. Poor recruitment (and retention) may
also lead to a trial being extended, increasing costs. Investi-
gators use many interventions to improve recruitment
[4-6] but evidence regarding the likely effect of these inter-
ventions is often unclear.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cause of the dispersed nature of both the recipients of ser-
vices and the professionals delivering the services [7].
Recruitment efforts can be hampered by actual or perceived
demands of transportation, unfamiliarity with study sites
for appointments, and inflexible appointment times within
working hours. The Cochrane review of interventions to
improve recruitment has a planned subgroup analysis com-
paring studies by setting (for example, community versus
secondary care recruitment) but has not found enough
community and primary care studies to include in the ana-
lysis, despite including a total of 45 studies [5]. More rigor-
ous evaluations of recruitment interventions are needed,
especially in community and primary care.
The BeWEL study was a multicentre RCT evaluating
the impact of a diet and physical activity intervention on
body weight in people who have had pre-cancerous bowel
polyps [8]. The relationship between diet, physical activity,
excess weight and increased risk of colorectal cancer (and
other chronic disease) is well described [9] and the Na-
tional Health Service (NHS) colorectal cancer screening
programme offers a timely opportunity to offer interven-
tion support. The aim was to recruit 316 eligible partici-
pants over a period of 12 months. However, obtaining the
necessary research governance and ethical approval went
more slowly than expected, which quickly led to a shorter
time frame to meet the recruitment target. This paper
aims to critically review the methods employed to over-
come this challenge and so provide insight into the impli-
cations for future trials.
Methods
BeWEL’s sample size was calculated on the basis of a clin-
ically important weight loss at 12 months of 7%, which at
80% power meant that 133 participants would be required
to complete each arm of the study. The target of 7%
weight loss at 12 months was chosen as this has been
found to be effective for diabetes prevention [10]. Allow-
ing for a dropout rate of 16%, as seen in the similar Bowel
Health to Better Health (BHBH) study [11], meant that
158 participants were required for each arm, giving a re-
cruitment target of 316. Individuals were eligible for the
trial if they were aged 50 to 74 years with a BMI greater
than 25 kg/m2 and had been found to have benign aden-
omas after a screening colonoscopy done as part of the
Scottish Bowel Screening Programme (http://www.bowel-
screening.scot.nhs.uk). Individuals also needed to have
been physically able to undertake the trial’s exercise re-
quirements and to be able to provide informed consent.
Individuals were not eligible for the trial if they had a nor-
mal colonoscopy, malignant lesion or insulin dependent
diabetes.
The participants for BeWEL were recruited through
the colonoscopy clinics of the Scottish Bowel ScreeningProgramme. The planned recruitment strategy [8] was
as follows:
1. A brief letter about BeWEL from the colorectal
cancer surgeon, enclosed with the screening results,
endorsing the study and encouraging the recipient
to read an information sheet that would be sent by
the study team within two weeks.
2. An information leaflet, letter of invitation, reply
slip and pre-paid envelope was then sent by the
study team.
3. Those indicating that they would like to take part
were screened for eligibility over the telephone by a
research nurse. Eligible individuals were then invited
to attend a study centre to provide consent and
undergo baseline measures.
4. Non-responders were sent a reminder after two
weeks, which included the information leaflet, letter
of invitation, reply slip and pre-paid envelope.
Based on this plan and an estimated positive response
rate of 70%, based on a previous study of diet and physical
activity [11], three colonoscopy clinics were recruited to
take part in the trial, one each in the Tayside, Forth Valley,
and Ayrshire and Arran regions of Scotland. Monthly trial
management group meetings monitored recruitment using
site-specific CONSORT diagrams, as well as a CONSORT
diagram for the trial as a whole.
Approvals
BeWEL was approved by the Tayside Committee on
Medical Research Ethics (Committee B), REC reference
10/S1402/34 and received research and development ap-
proval from NHS Ayrshire and Arran, NHS Forth Valley,
NHS Greater Glasgow and Clyde and NHS Tayside.
Results
A diagram of participant flow is given in Figure 1. A
total of 997 letters of invitation were sent between
November 2010 and April 2012 (17 months) to individ-
uals who had undergone colonoscopy following a posi-
tive faecal occult blood test as part of the Scottish
Bowel Screening Programme, had a diagnosis of aden-
oma confirmed by histopathology and were aged 50 to
74 years. To the best of our knowledge, these were all
the patients screened in the participating Health Boards
for whom an adenoma was detected. Of these, 492 re-
plied positively (49%) but 108 (22%) were ineligible as
their BMI was less than 25 kg/m2, 42 (9%) declined to
proceed after receiving detailed information of the re-
quirements and 13 (3%) replied after the recruitment
period had ended. Thus, 329 patients went on to be
randomized (33%), exceeding the target recruitment of
316. Retention was higher than estimated, leading to a
Figure 1 Participant flow through the trial. Where a number is marked as an estimate, this is the number we used pre-trial for planning.
* Participants attended the 12-month interview.
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sample size calculation (266) (Table 1).
Although the recruitment target was met, this was not
achieved without modifying the original recruitment plan.
The strategies introduced are listed in Table 2. Upon theTable 1 Estimates used in planning recruitment and the
numbers actually achieved in the trial
Recruitment assumption Estimate Actual
Loss to follow-up 16%a 7%
Consent rate 70%a 49%
Recruitment target 316 329
aData from [11].initial delayed start to recruitment, the first modification
was made, which was to approach new sites for recruitment
and begin the approvals process. By month three, the posi-
tive response and randomization rates were 31% and 17%,
respectively, indicating a need for further efforts to improve
recruitment. Strategies 2 to 8 were then introduced.
Strategy 1: New sites approached for study inclusion
Research staff in the UK who do not have contracts with
the NHS need a document called a ‘research passport’ be-
fore they can contact NHS patients or access their data
(see http://www.ukcrc.org/regulationgovernance/research-
passport/). Obtaining these documents took longer than
anticipated, meaning that recruitment to BeWEL at all sites
Table 2 Recruitment strategies employed in the BeWEL trial
Strategy number Strategy Date started
(month number)
1 New sites approached for study inclusion. November 2010 (month 1)
2 Research nurse telephones non-responders (suggested by [4,5]). January 2011 (month 3)
3 BMI cut-off at telephone screening reduced to 24 kg/m2 to avoid excluding
participants who had underestimated their BMI. Such participants were
invited to visit the research centre to have their eligibility confirmed.
January 2011 (month 3)
4 Frequency of visits by the trial manager to research
nurses and on-site NHS staff increased to monthly.
May 2011 (month 7)
5 Brief participant information leaflet introduced and printed on
high-quality paper with NHS logos. This was sent with the invitation
letter in hand-written envelopes (suggested by [12,13]).
June 2011 (month 8)
6 The local consultants’ names and their endorsement
of the study were added to the invitation letter.
June 2011 (month 8)
7 Eligible participants unable to travel to a study site
for assessments were offered home visits.
July 2011 (month 9)
8 Letters of congratulation were sent to sites for good recruitment. November 2011 (month 13)
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initial approach was made to Gartnavel General Hospital,
NHS Greater Glasgow and Clyde (GG&C), to discuss the
BeWEL study and seek approvals. By March 2011, a fur-
ther site in Fife had also been approached but the GG&C
site was still awaiting NHS research and development
(R&D) approvals. In April 2011, the Trial Steering Com-
mittee met and suggested that the site in Fife be kept on
hold and the study be extended for a short period to meet
its recruitment target rather than having to go through
the time-consuming permissions process. Subsequently,
an additional GG&C site (Victoria Infirmary) became in-
volved, through local consultant interest. Both additional
sites were positive and the process of gaining ethical ap-
proval was smooth. The process of gaining R&D approvals
and issuing research passports, as well as delays caused
through clinicians needing to provide paperwork, meant
that it took seven months and considerable effort from the
trial team to gain all the relevant permissions for Gartnavel
General Hospital (submitted November 2010 and approved
July 2011). The second of the two sites, Victoria Infirm-
ary, agreed to take part in September 2011 but obtain-
ing permissions took until 24 January 2012, with just
four months recruitment time remaining. By the end
of recruitment, only five participants were recruited
through the two Glasgow sites.
Strategy 2: Research nurse telephones non-responders
There is high-quality evidence that telephone reminders to
non-responders increase trial recruitment [4,5] and tele-
phone reminders were added to the protocol after the first
three months of recruitment. Two weeks after the re-
minder invitations were sent out, the research nurses tele-
phoned individuals who had not responded, up to a
maximum of three times over a two-week period. Thisrequired a change to the invitation letter to make it clear
that the trial team would telephone non-responders, and a
substantial amendment to be submitted to the ethics com-
mittee for approval (submitted 21 December 2010 and ap-
proved 24 January 2011). Telephone reminders were time
consuming but led to the recruitment of an additional 14
participants (Table 3).
Strategy 3: BMI cut-off at telephone screening reduced to
24 kg/m2
It is widely documented that there is a tendency for height
to be overestimated and weight to be underestimated,
such that self-reported BMI is often underestimated, espe-
cially in men [14]. The trial management group therefore
agreed that potential participants who self-reported their
BMI to be 24 to 25 kg/m2 be invited into the study centre
to have their eligibility checked. This resulted in screening
an additional 15 individuals, of whom ten were eligible
and all were recruited.
Strategy 4: Frequency of visits by the trial manager to
research nurses and on-site NHS staff increased to monthly
The trial manager was in daily email or telephone contact
with site research nurses to offer support as necessary. The
trial management group initiated monthly visits to sites by
the trial manager to offer face-to-face support to research
teams and to maintain the visibility of the trial at the sites.
In total, there were 17 visits to Ayrshire and Arran, 15 to
Forth Valley and six to GG&C. The situation for Tayside
was somewhat different, since the trial manager was based
at the same hospital and there was therefore very regular
contact between the trial manager and research nurse at
this site. Although the support and endorsement of consul-
tants at each site was essential, it was also important to es-
tablish good working relationships with all referring and
Table 3 Recruitment return of telephone reminders to non-responders to a postal reminder invitation
Site identifier:
health board
Number sent
reminder letter
Number of non-responders
to reminder letter (%)
Number of non-responders
telephoned (%)
Number not responding
to any calls (%)
Number recruited
after call (%)
Site 1: Tayside 141 70 (50) 27 (39) 4 (15) 0 (0)
Site 2: Forth valley 103 52 (50) 40 (77) 18 (45) 5 (13)
Site 3: Ayrshire & Arran* 67 33 (49) 28 (85) 2 (7) 9 (32)
Site 4: Greater Glasgow 7 7 (100) 3 (44) 0 (0) 0 (0)
Site 5: Greater Glasgow 2 1 (50) 0 (0) 0 (0) 0 (0)
Total 320 163 (51) 98 (60) 24 (24) 14 (14)
*Owing to a misunderstanding, Ayrshire and Arran only started to follow the telephone reminder protocol in July 2011, not January 2011, as at the other sites.
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employed to support research nurses and lifestyle counsel-
lors with the day-to-day running of the trial. Although sup-
porting these relationships was considered essential for the
success of BeWEL, there is very little published evidence
regarding their effect on recruitment [4-6]. A single study
has evaluated the effect of site initiation visits and found
that they did not increase recruitment [15]. That study’s
host trial was terminated early and the effect of repeat
visits on recruitment could not be studied.
Strategy 5: Brief participant information leaflet introduced
and printed on high-quality paper with NHS logos
The full participant information leaflet (PIL) was an eight-
page document covering all aspects of the trial, including
mandatory sections that were required for ethical ap-
proval. Although the evidence for trial recruitment benefit
(or harm) for short versus long PILs is unclear [4,5], there
is evidence that shorter questionnaires lead to higher re-
sponse rates [12,13]. A brief-two page PIL was also pre-
pared to be sent two weeks after the initial invitation letter.
In addition, the NHS logo was added to both the brief and
full PILs, to take advantage of positive feelings about the
NHS screening service that were reported during BeWEL’s
formative work. Finally, “Please note this study does not in-
volve any further bowel examination,” was added to the
brief PIL, as a number of participants had asked whether
they had to have another colonoscopy as part of the study.
Ethical approval was obtained to introduce the brief PIL on
the understanding that the full leaflet would be provided to
potential participants before consent was obtained. Intro-
ducing the brief PIL required submission of a substantial
amendment to the ethics committee for approval (submit-
ted 23 June 2011 and approved 29 June 2011).
Strategy 6: The local consultants’ names and their
endorsement of the study were added to the invitation letter
The invitation letter was amended to show the consultant’s
name and his endorsement of the study. This decision was
based on a belief that potential participants would be more
likely to respond to a letter signed by someone they recog-
nised. There is no compelling evidence for such an effect[13], although the possibility of a small benefit is not ruled
out completely. The strategy was, however, simple and
cheap to implement. This required a substantial amend-
ment to be submitted to the ethics committee for approval
(submitted 23 June 2011 and approved 29 June 2011).
Strategy 7: Eligible participants unable to travel to a
study site for assessments were offered home visits
Some participants in Ayrshire and Arran and in Tayside,
both large and rural areas, found it difficult to travel to a
study site for assessments. To address this, the protocol
was amended to include the possibility of home visits by re-
search nurses for participants in any of the areas taking part
in BeWEL. Ten participants opted to have home assess-
ments, all from Tayside. Adding home visits required a
substantial amendment to be submitted to the ethics com-
mittee for approval (submitted 29 June 2011 and approved
14 July 2011).
Strategy 8: Letters of congratulation to sites for
good recruitment
A total of six letters of congratulation were sent out to
participating sites (three to Tayside, three to Ayrshire and
Arran) between January and June 2012. The sites were
commended for their continued support for the study and
told how many of their referrals were eligible and had
given signed consent to participant in the BeWEL study.
Combined impact of the additional recruitment strategies
on accrual
The first and most lengthy recruitment strategy instigated
was the addition of two further sites. Figure 2 shows the
actual cumulative monthly recruitment along with planned
recruitment and estimated monthly recruitment if the two
Glasgow sites had begun recruiting in March 2011 (four
months after the start of the trial) under two scenarios. In
the first scenario (dotted line), the two Glasgow sites have
a combined recruitment equivalent to the average of the
monthly rates at the three other sites. In the second sce-
nario (dashed line), each of the Glasgow sites recruits at a
rate equivalent to the average of the monthly rates at the
other three sites (see Table 4). In the former scenario, the
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Figure 2 Planned, actual and estimated total monthly recruitment. The estimated monthly recruitment rate is based on two scenarios.
Scenario 1 (dotted line): the two Glasgow sites had a combined monthly recruitment rate equivalent to the average of the monthly rates at the
three other sites. Scenario 2 (dashed line): the two Glasgow sites each recruited at a similar rate to the other three sites.
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around three months earlier, in February 2012. In the latter
scenario, the recruitment target would have been reached
six months earlier, in November 2011, or just one month
behind the original schedule. Finally, the percentage of eli-
gible individuals who consented to take part and went on
to be randomized increased steadily throughout the trial
from 17% in Jan 2011 to 33% in May 2012, when the trial
reached its recruitment target (Figure 3).
Discussion
The BeWEL trial met its recruitment target. However, des-
pite close monitoring and considerable resources and effort
being targeted at recruitment, the trial still required a six
month no-cost extension from the funder to meet this tar-
get. Although the funder provided no additional funding,
extending the trial by six months was possible because of
flexibility shown by contracted staff and because core-
funded and other departmental staff contributed more time.
By three months into the trial, it was clear that recruitment
was not going as planned and a series of interventions to in-
crease recruitment were implemented, including interven-
tions with evidence of benefit from systematic reviews (for
example, telephone reminders to non-respondents [4,5]).
Whilst these probably helped, as demonstrated in Figure 3,
which shows a steady increase in the proportion of eligible
individuals consenting and being randomized, there was nomagic-bullet recruitment intervention that led to a step
change in recruitment rates. Some interventions required
substantial effort, such as repeated telephone attempts to
contact participants and visiting remote rural locations. It is
also clear that, as others have reported [16], recruitment in
the first couple of months or so is indicative of later recruit-
ment unless action is taken. To have assumed that slow re-
cruitment was merely trial growing pains rather than a
problem to be dealt with immediately would have been a
mistake.
There are essentially two issues at the heart of
BeWEL’s recruitment challenges:
1. Estimating the number of potentially eligible
participants who will agree to take part;
2. Introducing extra recruitment sites.Estimating the number of potentially eligible participants
who will agree to take part
The estimate of 200 patients diagnosed each year at the
three original sites turned out to be accurate but the
proportion who were eligible was 75%, not 81%, as esti-
mated. This relatively small difference was then com-
pounded by eligible participants who changed their
mind after initially saying yes (42, or 9%) to participa-
tion, which was not expected.
Table 4 Monthly recruitment figures by site, including estimated monthly recruitment at Greater Glasgow under two scenarios
Month Ayrshire &
Arran
Forth
valley
Tayside Actual,
greater Glasgow
Estimated, Greater
glasgow (scenario 1)
Estimated, greater
Glasgow (scenario 2)
Actual total
monthly recruitment
Estimated total monthly
recruitment (scenario 1)
Estimated total monthly
recruitment (scenario 2)
November 2010 0 0 1 0 0 0 1 1 1
December 2010 0 1 0 0 0 0 1 1 1
January 2011 2 7 3 0 0 0 12 12 12
February 2011 6 11 6 0 0 0 23 23 23
March 2011 3 6 10 0 6 13 19 25 32
April 2011 3 7 1 0 4 7 11 15 18
May 2011 3 7 7 0 6 11 17 23 28
June 2011 5 4 8 0 6 11 17 23 28
July 2011 9 6 8 0 8 15 23 31 38
August 2011 9 5 5 0 6 13 19 25 32
September 2011 7 8 3 0 6 12 18 24 30
October 2011 11 5 7 0 8 15 23 31 38
November 2011 6 7 6 1 6 13 20 25 32
December 2011 9 2 21 0 4 8 132 17
January 2012 3 1 4 0 3 5 8 11
February 2012 7 4 9 0 7 13 20 27
March 2012 7 6 10 0 8 15 23
April 2012 13 10 9 0 11 21 32
May 2012 18 3 4 4 8 17 29
Total 329 314 313
Scenario 1, the two Glasgow sites on board in March 2011 and have a combined recruitment equivalent to the average of the monthly rates at the three other sites; scenario 2, the two Glasgow sites on board in
March 2011 and recruit at a rate equivalent to the average of the monthly rates at the other three sites. In scenario 1, BeWEL would have reached its target about three months earlier; in scenario 2, the target would
have been met about six months earlier.
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was 49%, not the estimated 70%. Formative qualitative
research was conducted to help check the acceptability
of the intervention concept and to refine methods before
recruitment started [17]. This gave insight into how the
initial approach to patients could be improved; for ex-
ample, that colorectal cancer health professionals act as
advocates for the study and repeat its endorsement by
the lead clinician, suggestions that were incorporated
into the recruitment strategy for BeWEL. One important
finding from the formative research was that patients
had little understanding of the potential link between
adenoma risk and their own health behaviour, and con-
sequently struggled to see the relevance of an invitation
to participate in a lifestyle-change study. This was rein-
forced by the tendency of health professionals during
and after adenoma treatment to adopt a reassuring tone
that downplayed risk. The ‘all-clear’ messages that pa-
tients picked up from written and verbal communication
after their adenoma operation implied a ‘clean bill of
health’ and indicated that there was nothing about their
lifestyle requiring modification. Although efforts were
made in the trial recruitment process to address this
problem by making clearer the potential links between
adenoma risk and lifestyle behaviour, it is possible that
the link was still not sufficiently salient or believable for
some patients, and that this may have contributed to re-
luctance to participate in the study.
The estimated consent rate of 70% was based on the
BHBH study [11], a trial similar to BeWEL. The BHBH
study reported two consent rates: an overall rate of 51%
and an ‘initial’ rate of 68%; the latter rate was the rate seen
before a second Dundee-based trial started recruiting from
the same patient pool. The 68% rate seemed to be areasonable choice for BeWEL, given the clear link between
the fall in the BHBH study consent rate and the start of re-
cruitment by the second trial. As we found later, the overall
BHBH consent rate would have been a better bet. Addition-
ally, although the BHBH study was similar to BeWEL there
were two key differences. The first was that the BeWEL
intervention placed more demands on patients, requiring a
12-month commitment from participants rather than three.
The second was that weight management was included in
BeWEL but not in the earlier trial, which again might have
deterred some from participating. Although most of the
BeWEL participants who were interviewed at the end of
the program found the 12-month duration and inclusion of
weight management acceptable and not too onerous or in-
trusive, these were of course patients who had agreed to
participate; we do not know how many were put off coming
forward in the first place by the perceived demands of par-
ticipation in the study.
There are a couple of key lessons in this experience.
Firstly, how should investigators estimate consent rates?
One simple approach would be for investigators to esti-
mate no more than 50% unless they have experience of
higher consent from several studies in the same popula-
tion being recruited in the same setting. This appears ra-
ther arbitrary but a study of recruitment in 207 breast
cancer trials calculated the number needed to recruit one
additional participant for the 69 trials that provided suffi-
cient information to do the calculation and the result was
remarkably consistent, with a median of two individuals
being approached for every person recruited [18]. Gross
et al. [19] found a median of 1.8 (range, 1 to 68) for their
study of 172 trials, whereas Toerien et al. [20], in their
study of 133 trials, found that investigators assessed a me-
dian of 230% of their target number. A consent rate
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the absence of compelling evidence upon which to base it.
More compelling evidence would comprise data from two
or more studies that have recruited the same population,
in the same setting, using the same sort of staff, for the
same sort of intervention and all within recent history.
Even with these data, investigators would need to make
evidence-informed, judgement-based decisions about the
similarity between earlier recruitment contexts and their
own. It would be possible to put confidence intervals
around consent rates from other studies, including pooled
estimates, but it is context, not statistical uncertainty, that
is likely to be the main driver of variability in consent
rates. It is far from clear that taking the lower bound of
the confidence interval would provide more reassurance
than would be the case if investigators (ourselves included)
were simply more conservative when estimating consent
rates, and many other parameters besides. The best ap-
proach to consent rate planning remains in-context pilot
work prior to the full-scale trial.
The second lesson was that once it became apparent that
fewer patients were consenting to take part, one additional
strategy would have been to conduct a second stage of
qualitative research. This need not have been a major exer-
cise, as one or two focus groups or a small number of indi-
vidual interviews would have sufficed. This second stage
could have focused on exploring the views of those patients
who expressed an initial interest but then did not follow
through, to see whether any of the reasons for reluctance
were amenable to action. This kind of research exercise has
been used to explore how patients interpret and respond to
informed consent materials provided in clinical trials [21].
‘Consumer research’ of this sort could play a valuable role
throughout the development and implementation of an
intervention in remedying problems as they occur. Indeed,
given the commonplace nature of trial process problems,
investigators would do well to build in the possibility of
adding rapid, response-mode qualitative work to their ini-
tial ethical and other approval submissions.
Bringing on extra sites
There were 13 months between the trial management
team’s first discussion with a Glasgow site and the first
Glasgow recruit. At the end of the trial, the two sites to-
gether had been able to recruit only five participants. Con-
jecture as to what might have been is, perhaps, of limited
utility but had the two extra sites both recruited at a similar
rate to the other sites (Scenario 2 in Figure 2 and Table 4),
then the trial would have met its target only one month be-
hind the original recruitment schedule. In the three original
sites, considerable negotiation had been undertaken well
before the funding bid had been submitted, and again after
the funding award announced, highlighting the time re-
quired to match sites to study requirements. Thus, by thetime the study started, the preparatory work at each site
had been undertaken. This was not the case in the two
Glasgow sites, where many months were taken up as a con-
sequence of NHS R&D departmental work practices being
different from other sites, a situation made worse by the
loss of the trial manager to take up another post during the
latter stage of funding negotiations. Moreover, the antici-
pated time for recruitment from these two sites was not
fully factored in to the revised recruitment plan.
This experience points towards a number of sugges-
tions linked to site selection:
 Identify more sites than are expected based on pre-
trial assumptions as an insurance policy against
those assumptions proving incorrect. The number of
extra sites will depend on how confident investiga-
tors are about their pre-trial assumptions. If all, or
some of the approvals for these sites can be obtained
up-front (that is, before they are actually needed), so
much the better.
 Formally assess all sites for suitability for the trial.
The trial team should use a checklist of key features
of a site that they believe are essential for successful
participation. The team could develop its own
checklist, or modify an existing one (for examples,
see Warden et al. [22]).
 Sites that do not meet the requirements listed on the
checklist should be reviewed to determine whether
measures could be put in place by the trial team to
support the site in meeting the checklist criteria. If
not, the site should not be considered for the trial.
Clearly, no site is ideal for all trials but there is grow-
ing agreement that sites should be selected based on a
formal assessment of their past performance and the
likelihood of success in the trial being planned [22-24].
As Shah pointed out in a recent roundtable discussion
of heart failure trials [23]:
‘There is a peculiar paradox that exists in trial
execution - we perform clinical trials to generate evi-
dence to improve patient outcomes; however, we conduct
clinical trials like anecdotal medicine: (1) we do what
we think works; (2) we rely on experience and judgement
and (3) limited data to support best practices.’
What features of a site might predict its future perform-
ance in a given trial is worthy of more research but some
features that may be relevant [22-24] include:
 Previous experience with multicentre trials;
 Familiarity of operating a trial protocol and the
closeness of the trial protocol to the clinical
procedures currently in place at the site;
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 Previous recruitment performance;
 Case mix and access to eligible participants;
 Availability of resources such as research nurses, study
coordinators, research pharmacists, administrators;
 Lack of competing demands that would hinder the
site’s ability to fully engage with the trial.
Future research could focus on systematically reviewing
the trial management literature for studies in order to
evaluate formal site-selection methods and develop predic-
tion rules and metrics that can be used for site selection.
Conclusions
Recruitment plans rarely survive contact with actual partici-
pants [2]. Though challenging, recruitment to multicentre
trials can be successfully achieved with a committed team.
In a UK context, NHS R&D management approval can be
a substantial source of delay, whilst obtaining ethical ap-
proval is a much smoother process. Investigators should be
cautious when estimating consent rates and it may be bene-
ficial to do qualitative work during the trial if consent rates
are less than expected, to try and identify the reason. Fi-
nally, investigators should select trial sites on the basis of a
formal assessment of a site’s past performance and the like-
lihood of success in the trial being planned.
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